ReviewNature reviews. Rheumatology2013
Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.
Review in Nature reviews. Rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- Nontuberculous mycobacterium seroprevalence in Japanese patients with RA.Rheumatology advances in practice · 2026Article
- Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis.RMD open · 2024Article
- Clinical course of nontuberculous mycobacterial pulmonary disease in patients with rheumatoid arthritis.Advances in rheumatology (London, England) · 2024Article
- Review
- TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.Scientific reports · 2022Observational
- Modulating macrophage function to reinforce host innate resistance againstFrontiers in immunology · 2022Review
- Development of Rheumatoid Arthritis in CavitaryInfection and drug resistance · 2022Article
- Article
- Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.The Journal of infectious diseases · 2020Article
- The Rise of Non-Tuberculosis Mycobacterial Lung Disease.Frontiers in immunology · 2020Review
- Obstructive lung diseases and risk of rheumatoid arthritis.Expert review of clinical immunology · 2020Review
- Impact of Host Genetics and Biological Response Modifiers on Respiratory Tract Infections.Frontiers in immunology · 2019Review
- Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies.Frontiers in immunology · 2019Review
- Mycobacterium Avium Prosthetic Hip Infection on Abatacept Presenting as Fever of Unknown Origin.Journal of bone and joint infection · 2019Article
- Immunological roulette: Luck or something more? Considering the connections between host and environment in TB.Cellular & molecular immunology · 2018Review
- [Nontuberculous mycobacterial infections].Zeitschrift fur Rheumatologie · 2017Review
- Prosthetic Joint Infection due toCase reports in infectious diseases · 2017Article
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.Annals of the rheumatic diseases · 2016Review
- '"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection.BMC medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In modern times a relationship between tuberculosis (TB) and rheumatoid arthritis (RA) has been firmly recognized, and is primarily attributable to the immunosuppressive therapies used to treat RA. Whereas TB can complicate the successful management of RA, nontuberculous mycobacteria have now perhaps become as important as (if not more so than) TB in the setting of RA, and can represent an even greater challenge to the rheumatologist wishing to use immunosuppressive therapies. This article reviews our most recent understanding of the epidemiological and clinical aspects of mycobacterial disease as it relates to RA, and the existing and emerging immunosuppressive therapies used to treat this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.